Evidence map›Paper›PMID 35270201›Full record

Observational studyInternational journal of environmental research and public health2022

Using Generic and Disease-Specific Measures to Assess Quality of Life before and after 12 Months of Hearing Implant Use: A Prospective, Longitudinal, Multicenter, Observational Clinical Study.

Luis Lassaletta, Miryam Calvino, Isabel Sanchez-Cuadrado, Piotr Henryk Skarzynski, Katarzyna B Cywka, Natalia Czajka, Justyna Kutyba, Dayse Tavora-Vieira, Paul van de Heyning, Griet Mertens and 7 more

Open access · goldAbstract readMulticenter StudyObservational Study
In one paragraph

Observational study in International journal of environmental research and public health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
1.3field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Long-Term Non-Users of Transcutaneous Auditory Implants: Thirty Years of Experience at a Single Institution.International journal of environmental research and public health · 2023
    Article
  6. New technology can benefit established middle ear implant users: Samba 2 vs previous models of audio processors for Vibrant Soundbridge.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2023
    Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 9 institutions in 8 countries.

Luis LassalettaDepartment of Otorhinolaryngology, Hospital La Paz. IdiPAZ Research Institute, 28046 Madrid, Spain.
Miryam CalvinoDepartment of Otorhinolaryngology, Hospital La Paz. IdiPAZ Research Institute, 28046 Madrid, Spain.ORCID 0000-0002-3301-2185
Isabel Sanchez-CuadradoDepartment of Otorhinolaryngology, Hospital La Paz. IdiPAZ Research Institute, 28046 Madrid, Spain.
Piotr Henryk SkarzynskiInstitute of Physiology and Pathology of Hearing, World Hearing Center, 05-830 Kajetany, Poland.ORCID 0000-0002-4978-1915
Katarzyna B CywkaInstitute of Physiology and Pathology of Hearing, World Hearing Center, 05-830 Kajetany, Poland.ORCID 0000-0003-1224-1074
Natalia CzajkaInstitute of Physiology and Pathology of Hearing, World Hearing Center, 05-830 Kajetany, Poland.
Justyna KutybaInstitute of Physiology and Pathology of Hearing, World Hearing Center, 05-830 Kajetany, Poland.ORCID 0000-0002-7828-3712
Dayse Tavora-VieiraFiona Stanley Fremantle Hospitals Group, Perth 6150, Australia.ORCID 0000-0001-6249-7268
Paul van de HeyningDepartment of Otorhinolaryngology, Antwerp University Hospital, 2650 Antwerp, Belgium.
Griet MertensDepartment of Otorhinolaryngology, Antwerp University Hospital, 2650 Antwerp, Belgium.
Hinrich StaeckerENT Department, University of Kansas Medical Centre, Kansas City, KS 66160, USA.ORCID 0000-0002-0348-3015
Bryan HumphreyENT Department, University of Kansas Medical Centre, Kansas City, KS 66160, USA.
Mario ZernottiDepartment of Otorhinolaryngology, Sanatorio Allende de Córdoba, Córdoba 5000, Argentina.
Maximo ZernottiDepartment of Otorhinolaryngology, Sanatorio Allende de Córdoba, Córdoba 5000, Argentina.
Astrid MageleENT Department, Universitätsklinikum St. Pölten, 3100 St. Pölten, Austria.
Marlene PloderENT Department, Universitätsklinikum St. Pölten, 3100 St. Pölten, Austria.
Julia Speranza ZabeuHospital de Reabilitacão de Anomalias Craniofaciais da Universidade de Sao Paulo, Campus Bauru, Bauru 17012-230, Brazil.
Institute of Physiology and Pathology of Hearing · PLAntwerp University Hospital · BEFundacion Allende · ARInstituto de Salud Carlos III · ESUniversitätsklinikum St. Pölten · ATUniversity of Kansas Medical Center · USFiona Stanley Hospital · AUHospital La Paz Institute for Health Research · ESUniversidade de São Paulo · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The primary objectives of this study were to evaluate the effect of hearing implant (HI) use on quality of life (QoL) and to determine which QoL measure(s) quantify QoL with greater sensitivity in users of different types of HIs. Participants were adult cochlear implant (CI), active middle ear implant (VIBRANT SOUNDBRIDGE (VSB)), or active transcutaneous bone conduction implant (the BONEBRIDGE (BB)) recipients. Generic QoL and disease-specific QoL were assessed at three intervals: pre-activation, 6 months of device use, and 12 months of device use. 169 participants completed the study (110 CI, 18VSB, and 41BB). CI users' QoL significantly increased from 0-6 m device use on both the generic- and the disease-specific measures. On some device-specific measures, their QoL also significantly increased between 6 and 12 m device use. VSB users' QoL significantly increased between all tested intervals with the disease-specific measure but not the generic measure. BB users' QoL significantly increased from 0-6 m device use on both the generic- and the disease-specific measures. In sum, HI users experienced significant postoperative increases in QoL within their first 12 m of device use, especially when disease-specific measures were used. Disease-specific QoL measures appeared to be more sensitive than their generic counterparts.

Indexed as

Cochlear ImplantationCochlear ImplantsAdultHearingHumansProspective StudiesQuality of LifeBONEBRIDGEcochlear implantpatient-reported outcomes (PRO)quality of lifeSOUNDBRIDGE

Identifiers

PMID35270201
PMCPMC8909702
OpenAlexW4214615415

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.